{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"vip-ibd","title":"VIP for IBD: Evidence Graded Review of Vasoactive Intestinal Peptide in Crohn's Disease and Colitis","body":"## What's breaking down if you have IBD (Crohn's / colitis)\n\nIf your intestinal lining loses barrier integrity, immune cells over-respond and inflammation persists. Epithelial cells fail to repair quickly enough. Nerve signaling in the gut wall shifts. These layers compound: barrier leak allows more triggers, immune imbalance sustains damage, and autonomic control of motility and secretion falters. Regeneration falls behind degeneration, so the condition continues.\n\n## Why VIP might help you\n\n1. You are reading about IBD (Crohn's / colitis) — what breaks down matters before any compound name.\n2. Therefore for you: If the immune / autonomic layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\n\nIf immune over-activation drives your mucosal damage, VIP pathways connect to reduced pro-inflammatory signals and better epithelial recovery in studied models. If autonomic imbalance affects gut motility or secretion, VIP's natural role in those systems aligns with restoring balance rather than suppression alone.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- VIP → immune / autonomic\n\n## What the evidence actually shows\n\nHuman data: Observational only. One cross-sectional and prospective study of 115 adults with IBD measured VIP concentrations and found variable plasma levels that differed by disease severity (source s1). Another examined VIP nerves in Crohn's tissue and noted consistent increases and abnormal appearance in rectal samples (source s2). These show associations, not treatment effects.\n\nPreclinical data: Multiple mouse and rat studies. In TNBS-induced colitis (model sharing features with Crohn's), VIP treatment reduced clinical signs including weight loss, diarrhea, and histologic inflammation (source s3). VIP nanomedicine in DSS and TNBS mouse colitis lowered pro-inflammatory cytokines, improved histology, and supported tight junction proteins (source s4). VIP-deficient mice showed greater susceptibility to chemically induced colitis in some experiments, with exogenous VIP rescuing barrier features (source s5). Results are mixed across studies; some report exacerbation depending on model and microbiota (source s5).\n\nAnecdotal data: Limited. One Reddit thread states VIP is among the better researched compounds for Crohn's via upstream immune effects on gut lining (source s6). Other posts discuss VIP in unrelated contexts such as CIRS or Raynaud's with no IBD-specific outcomes reported.\n\n## What scientists say\n\nResearchers note VIP's immunomodulatory properties in colitis models and suggest it as a candidate for further testing in Crohn's, while highlighting inconsistent findings in knockout models and human expression data (sources s3, s5). Emphasis remains on preclinical promise rather than clinical translation.\n\n## What people say on Reddit\n\nDiscussions are sparse. Users mention VIP's anti-inflammatory profile and one notes specific research interest in Crohn's. No detailed personal outcome reports tied to IBD treatment appear in top results.\n\n## What people say on X\n\nNo relevant patient experiences or outcome reports surfaced in searches for VIP in IBD contexts.\n\n## What we do not know\n\nNo published human intervention trials test VIP administration for IBD symptom control or mucosal healing. Optimal delivery, duration, and patient selection remain untested in controlled settings. Long-term effects on human gut microbiota or barrier repair are unknown.\n\n## Safety and limits\n\nVIP is a naturally occurring peptide with documented effects in animal colitis models, but human safety data for therapeutic use in IBD do not exist in the reviewed sources. Observational human studies report no direct safety signals from measurement alone. All therapeutic claims rest on preclinical work.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/vip-ibd/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"VIP treatment reduced clinical and histologic severity in TNBS-induced colitis in mice.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Direct evidence of repair pathway effects in a Crohn's-like model.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:29:34.913Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"VIP nanomedicine lowered inflammation markers and improved barrier proteins in DSS and TNBS mouse colitis.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s4"],"source_status":"sourced","why_material":"Shows tissue-level repair signals beyond symptom masking.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:29:34.913Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"VIP plasma levels vary with IBD severity in a study of 115 patients.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Observational association only; no treatment data.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:29:34.913Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"VIP nerve changes observed in Crohn's rectal tissue samples.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Tissue-level observation in patients.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:29:34.913Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"VIP-deficient mice exhibit increased susceptibility to chemically induced colitis in some models.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s5"],"source_status":"sourced","why_material":"Supports role in barrier maintenance.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:29:34.913Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c6","text":"Reddit users note VIP research relevance to Crohn's via immune effects on gut lining.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s6"],"source_status":"sourced","why_material":"Community discussion, not outcome data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:29:34.913Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/2791804/","title":"Vasoactive intestinal peptide as a laboratory supplement to clinical testing in inflammatory bowel disease","quote":"One hundred-fifteen adult IBD patients were studied cross-sectionally and prospectively, 48 with ulcerative colitis (UC) and 67 with Crohn's disease (CD).","summary":"Observational measurement of VIP in IBD patients.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:29:32.935Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"fee95fb26e17ba61c05e452055063c3908e4ebd22d57d53cd82a56ef6e993b4e"},{"id":"s2","type":"pubmed","url":"https://gut.bmj.com/content/25/1/57","title":"Vasoactive intestinal peptide concentrations and immunocytochemistry in the colon of patients with Crohn's disease","quote":"Immunocytochemistry revealed a consistent increase in, and abnormal appearance of, VIP nerves in patients with Crohn's disease not only those with rectal...","summary":"Tissue findings in Crohn's patients.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:29:32.935Z","link_status":"http_403","quote_status":"unverified","prev":"fee95fb26e17ba61c05e452055063c3908e4ebd22d57d53cd82a56ef6e993b4e","hash":"d52d9ae4269ca5e80ee1e794e78b6d34d032d7b686efb06d6b9ae55e149de473"},{"id":"s3","type":"pubmed","url":"https://www.gastrojournal.org/article/S0016-5085(03)00055-6/fulltext","title":"Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease","quote":"Treatment with VIP reduced the clinical and histopathologic severity of TNBS-induced colitis, abrogating body weight loss, diarrhea, and macroscopic and microscopic intestinal inflammation.","summary":"Mouse TNBS colitis study showing reduced severity.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:29:32.935Z","link_status":"http_403","quote_status":"unverified","prev":"d52d9ae4269ca5e80ee1e794e78b6d34d032d7b686efb06d6b9ae55e149de473","hash":"126f99982f20657e48b5770f8c0e525f89652a833a8c0ecdf30fb69b7d4cdfb4"},{"id":"s4","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6053281/","title":"Vasoactive Intestinal Peptide Nanomedicine for the Treatment of Inflammatory Bowel Disease","quote":"We demonstrate the therapeutic benefit of VIP-SSM over free peptide in reversing severe colitis associated with IBD.","summary":"Nanomedicine improved inflammation and barrier markers in mouse models.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:29:32.935Z","link_status":"ok","quote_status":"verified","prev":"126f99982f20657e48b5770f8c0e525f89652a833a8c0ecdf30fb69b7d4cdfb4","hash":"4b8b21ae33c77c99fc987b09fd23dc1187bad497c4a9b03692618a2bcf8edbbc"},{"id":"s5","type":"pubmed","url":"https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2019.02689/full","title":"Vasoactive Intestinal Peptide Deficiency Is Associated With Dysbiosis and Altered Short-Chain Fatty Acid Levels in the Gastrointestinal Tract","quote":"In some studies, VIP knockout mice were more susceptible to chemically-induced intestinal inflammation, and human inflammatory bowel disease (IBD) patients show a reduction in VIP positive nerves proximal to severe mucosal damage.","summary":"Reviews mixed preclinical and human expression data.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:29:32.935Z","link_status":"ok","quote_status":"verified","prev":"4b8b21ae33c77c99fc987b09fd23dc1187bad497c4a9b03692618a2bcf8edbbc","hash":"ca265033e771dbdca1d8650d256ae91c52e1b1619fb4bb52da0404dc97aa1952"},{"id":"s6","type":"reddit","url":"https://www.reddit.com/r/Biohack_Blueprint/comments/1u31ihv/the_peptide_nobody_talks_about_but_everyone/","title":"The peptide nobody talks about but everyone should: VIP","quote":"VIP is actually one of the better researched compounds for Crohn's specifically. it works upstream on the immune response in the gut lining ...","summary":"Community comment on research relevance.","claim_ids":["c6"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:29:32.935Z","link_status":"ok","quote_status":"unverified","prev":"ca265033e771dbdca1d8650d256ae91c52e1b1619fb4bb52da0404dc97aa1952","hash":"d7f83bf06126e68fe70ae305e514ea16679779771ba4acf1b2066ac59b3a3eee"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T22:29:35.771Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"VIP for IBD: Evidence Graded Review of Vasoactive Intestinal Peptide in Crohn's Disease and Colitis","register":"source_ledger","body":"## What's breaking down if you have IBD (Crohn's / colitis)\n\nIf your intestinal lining loses barrier integrity, immune cells over-respond and inflammation persists. Epithelial cells fail to repair quickly enough. Nerve signaling in the gut wall shifts. These layers compound: barrier leak allows more triggers, immune imbalance sustains damage, and autonomic control of motility and secretion falters. Regeneration falls behind degeneration, so the condition continues.\n\n## Why VIP might help you\n\n1. You are reading about IBD (Crohn's / colitis) — what breaks down matters before any compound name.\n2. Therefore for you: If the immune / autonomic layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\n\nIf immune over-activation drives your mucosal damage, VIP pathways connect to reduced pro-inflammatory signals and better epithelial recovery in studied models. If autonomic imbalance affects gut motility or secretion, VIP's natural role in those systems aligns with restoring balance rather than suppression alone.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- VIP → immune / autonomic\n\n## What the evidence actually shows\n\nHuman data: Observational only. One cross-sectional and prospective study of 115 adults with IBD measured VIP concentrations and found variable plasma levels that differed by disease severity (source s1). Another examined VIP nerves in Crohn's tissue and noted consistent increases and abnormal appearance in rectal samples (source s2). These show associations, not treatment effects.\n\nPreclinical data: Multiple mouse and rat studies. In TNBS-induced colitis (model sharing features with Crohn's), VIP treatment reduced clinical signs including weight loss, diarrhea, and histologic inflammation (source s3). VIP nanomedicine in DSS and TNBS mouse colitis lowered pro-inflammatory cytokines, improved histology, and supported tight junction proteins (source s4). VIP-deficient mice showed greater susceptibility to chemically induced colitis in some experiments, with exogenous VIP rescuing barrier features (source s5). Results are mixed across studies; some report exacerbation depending on model and microbiota (source s5).\n\nAnecdotal data: Limited. One Reddit thread states VIP is among the better researched compounds for Crohn's via upstream immune effects on gut lining (source s6). Other posts discuss VIP in unrelated contexts such as CIRS or Raynaud's with no IBD-specific outcomes reported.\n\n## What scientists say\n\nResearchers note VIP's immunomodulatory properties in colitis models and suggest it as a candidate for further testing in Crohn's, while highlighting inconsistent findings in knockout models and human expression data (sources s3, s5). Emphasis remains on preclinical promise rather than clinical translation.\n\n## What people say on Reddit\n\nDiscussions are sparse. Users mention VIP's anti-inflammatory profile and one notes specific research interest in Crohn's. No detailed personal outcome reports tied to IBD treatment appear in top results.\n\n## What people say on X\n\nNo relevant patient experiences or outcome reports surfaced in searches for VIP in IBD contexts.\n\n## What we do not know\n\nNo published human intervention trials test VIP administration for IBD symptom control or mucosal healing. Optimal delivery, duration, and patient selection remain untested in controlled settings. Long-term effects on human gut microbiota or barrier repair are unknown.\n\n## Safety and limits\n\nVIP is a naturally occurring peptide with documented effects in animal colitis models, but human safety data for therapeutic use in IBD do not exist in the reviewed sources. Observational human studies report no direct safety signals from measurement alone. All therapeutic claims rest on preclinical work.","claims":[{"id":"c1","text":"VIP treatment reduced clinical and histologic severity in TNBS-induced colitis in mice.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Direct evidence of repair pathway effects in a Crohn's-like model.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:29:34.913Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"VIP nanomedicine lowered inflammation markers and improved barrier proteins in DSS and TNBS mouse colitis.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s4"],"source_status":"sourced","why_material":"Shows tissue-level repair signals beyond symptom masking.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:29:34.913Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"VIP plasma levels vary with IBD severity in a study of 115 patients.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Observational association only; no treatment data.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:29:34.913Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"VIP nerve changes observed in Crohn's rectal tissue samples.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Tissue-level observation in patients.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:29:34.913Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"VIP-deficient mice exhibit increased susceptibility to chemically induced colitis in some models.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s5"],"source_status":"sourced","why_material":"Supports role in barrier maintenance.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:29:34.913Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c6","text":"Reddit users note VIP research relevance to Crohn's via immune effects on gut lining.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s6"],"source_status":"sourced","why_material":"Community discussion, not outcome data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:29:34.913Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/2791804/","title":"Vasoactive intestinal peptide as a laboratory supplement to clinical testing in inflammatory bowel disease","quote":"One hundred-fifteen adult IBD patients were studied cross-sectionally and prospectively, 48 with ulcerative colitis (UC) and 67 with Crohn's disease (CD).","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"pubmed","url":"https://gut.bmj.com/content/25/1/57","title":"Vasoactive intestinal peptide concentrations and immunocytochemistry in the colon of patients with Crohn's disease","quote":"Immunocytochemistry revealed a consistent increase in, and abnormal appearance of, VIP nerves in patients with Crohn's disease not only those with rectal...","link_status":"http_403","quote_status":"unverified"},{"id":"s3","type":"pubmed","url":"https://www.gastrojournal.org/article/S0016-5085(03)00055-6/fulltext","title":"Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease","quote":"Treatment with VIP reduced the clinical and histopathologic severity of TNBS-induced colitis, abrogating body weight loss, diarrhea, and macroscopic and microscopic intestinal inflammation.","link_status":"http_403","quote_status":"unverified"},{"id":"s4","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6053281/","title":"Vasoactive Intestinal Peptide Nanomedicine for the Treatment of Inflammatory Bowel Disease","quote":"We demonstrate the therapeutic benefit of VIP-SSM over free peptide in reversing severe colitis associated with IBD.","link_status":"ok","quote_status":"verified"},{"id":"s5","type":"pubmed","url":"https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2019.02689/full","title":"Vasoactive Intestinal Peptide Deficiency Is Associated With Dysbiosis and Altered Short-Chain Fatty Acid Levels in the Gastrointestinal Tract","quote":"In some studies, VIP knockout mice were more susceptible to chemically-induced intestinal inflammation, and human inflammatory bowel disease (IBD) patients show a reduction in VIP positive nerves proximal to severe mucosal damage.","link_status":"ok","quote_status":"verified"},{"id":"s6","type":"reddit","url":"https://www.reddit.com/r/Biohack_Blueprint/comments/1u31ihv/the_peptide_nobody_talks_about_but_everyone/","title":"The peptide nobody talks about but everyone should: VIP","quote":"VIP is actually one of the better researched compounds for Crohn's specifically. it works upstream on the immune response in the gut lining ...","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":14853,"tokens_out":2907,"cost":0.02583375,"prev_hash":"genesis","hash":"9e77f76cd4856e628f36d3959103976cd6901a0b2ca51a65441ee0e0e0af165c"}],"provenance":[{"ts":"2026-06-29T22:29:35.771Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Vip for Ibd\nSlug: vip-ibd\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_cross\",\"condition\":\"IBD (Crohn's / colitis)\",\"condition_key\":\"ibd-crohns-colitis\",\"primary_peptide\":\"vip\",\"peptides_in_scope\":[{\"id\":\"vip\",\"name\":\"VIP\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down if you have IBD (Crohn's / colitis)\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"vip\",\"name\":\"VIP\",\"section_title\":\"Why VIP might help you\",\"layer\":\"immune / autonomic\",\"steps\":[\"You are reading about **IBD (Crohn's / colitis)** — what breaks down matters before any compound name.\",\"**Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. You are reading about **IBD (Crohn's / colitis)** — what breaks down matters before any compound name.\\n2. **Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **VIP** → immune / autonomic\",\"section_headings\":[\"What's breaking down if you have IBD (Crohn's / colitis)\",\"Why VIP might help you\",\"How these fit together\",\"What the evidence actually show","response":"{\n  \"slug\": \"vip-ibd\",\n  \"title\": \"VIP for IBD: Evidence Graded Review of Vasoactive Intestinal Peptide in Crohn's Disease and Colitis\",\n  \"body\": \"## What's breaking down if you have IBD (Crohn's / colitis)\\n\\nIf your intestinal lining loses barrier integrity, immune cells over-respond and inflammation persists. Epithelial cells fail to repair quickly enough. Nerve signaling in the gut wall shifts. These layers compound: barrier leak allows more triggers, immune imbalance sustains damage, and autonomic control of motility and secretion falters. Regeneration falls behind degeneration, so the condition continues.\\n\\n## Why VIP might help you\\n\\n1. You are reading about IBD (Crohn's / colitis) — what breaks down matters before any compound name.\\n2. Therefore for you: If the immune / autonomic layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\\n\\nIf immune over-activation drives your mucosal damage, VIP pathways connect to reduced pro-inflammatory signals and better epithelial recovery in studied models. If autonomic imbalance affects gut motility or secretion, VIP's natural role in those systems aligns with restoring balance rather than suppression alone.\\n\\n## How these fit together\\n\\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- VIP → immune / autonomic\\n\\n## What the evidence actually shows\\n\\nHuman data: Observational only. One cross-sectional and prospective study of 115 adults with IBD measured VIP concentrations and found variable plasma levels that differed by disease severity (source s1). Another examined VIP nerves in Crohn's tissue and noted consistent increases and abnormal appearance in rectal samples (source s2). These show associations, not treatment effects.\\n\\nPreclinical data: Multiple mouse and rat studies. In TNBS-induced colitis (model sharing features with Crohn's), VIP treatment reduc","tokens_in":14853,"tokens_out":2907,"cost":0,"prev":"genesis","hash":"a94782d019f0b75f086062abb34cf43f39739266220e124c6161e8416bae1a8e"},{"ts":"2026-07-17T02:43:24.692Z","model":"owner","action":"voxel_divide","prompt":"","input":"vip-ibd","response":"22 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"a94782d019f0b75f086062abb34cf43f39739266220e124c6161e8416bae1a8e","hash":"f166b51d2487059804034ffaec44d3ff5d841148eed249f8cfe00dd198300320"}],"energy":{"passes":2,"tokens_in":14853,"tokens_out":2907,"tokens_total":17760,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"f166b51d2487059804034ffaec44d3ff5d841148eed249f8cfe00dd198300320"},"posted_at":"2026-06-29T21:33:50.665Z","created_at":"2026-06-29T21:33:50.665Z","updated_at":"2026-07-17T02:43:24.692Z","machine":{"shape":"article.machine/v1","slug":"vip-ibd","kind":"article","read":{"human":"https://miscsubjects.com/a/vip-ibd","json":"https://miscsubjects.com/api/articles/vip-ibd","bundle":"https://miscsubjects.com/api/articles/vip-ibd/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":6,"sources":6,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/vip-ibd/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=vip-ibd","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"vip-ibd\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"vip-ibd\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/vip-ibd/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"vip-ibd\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/vip-ibd | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/vip-ibd","json":"/api/articles/vip-ibd","markdown":"/api/articles/vip-ibd/bundle?format=markdown","skill":"/api/articles/vip-ibd/skill","topology":"/api/articles/vip-ibd/topology","versions":"/api/articles/vip-ibd/revisions","invocations":"/api/articles/vip-ibd/invocations"},"editorial_review":null,"editorial_audit":{"slug":"vip-ibd","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"15b4fea8778d13c60a77d0ea1bd5a2f73797e66a1cdbaff3b0a6889bfe9df25e","object":{"object_type":"article-object","identity":{"id":"article:vip-ibd","slug":"vip-ibd","title":"VIP for IBD: Evidence Graded Review of Vasoactive Intestinal Peptide in Crohn's Disease and Colitis"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/vip-ibd","role":"explain","audience":"human"},"skill":{"route":"/api/articles/vip-ibd/skill","role":"direct behavior","audience":"model","content":"---\nname: vip-ibd\ndescription: Apply the VIP for IBD: Evidence Graded Review of Vasoactive Intestinal Peptide in Crohn's Disease and Colitis article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# VIP for IBD: Evidence Graded Review of Vasoactive Intestinal Peptide in Crohn's Disease and Colitis\n\nThis Skill is the behavioral expression of [the canonical article](/a/vip-ibd). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/vip-ibd.\n- Read claims and relationships at /api/articles/vip-ibd/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down if you have IBD Crohn's / colitis If your intestinal lining loses barrier integrity, immune cells over-respond and inflammation persists. Epithelial cells fail to repair quickly enough. Nerve signaling in the gut wall s\n\n## Representations\n\n- Human: /a/vip-ibd\n- JSON: /api/articles/vip-ibd\n- Relationships: /api/articles/vip-ibd/topology\n- History: /api/articles/vip-ibd/revisions\n"},"json":{"route":"/api/articles/vip-ibd","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/vip-ibd/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","vip","ibd"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/vip-ibd/invocations?status=success","failure_events":"/api/articles/vip-ibd/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"vip-ibd","title":"VIP for IBD: Evidence Graded Review of Vasoactive Intestinal Peptide in Crohn's Disease and Colitis","body":"## What's breaking down if you have IBD (Crohn's / colitis)\n\nIf your intestinal lining loses barrier integrity, immune cells over-respond and inflammation persists. Epithelial cells fail to repair quickly enough. Nerve signaling in the gut wall shifts. These layers compound: barrier leak allows more triggers, immune imbalance sustains damage, and autonomic control of motility and secretion falters. Regeneration falls behind degeneration, so the condition continues.\n\n## Why VIP might help you\n\n1. You are reading about IBD (Crohn's / colitis) — what breaks down matters before any compound name.\n2. Therefore for you: If the immune / autonomic layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\n\nIf immune over-activation drives your mucosal damage, VIP pathways connect to reduced pro-inflammatory signals and better epithelial recovery in studied models. If autonomic imbalance affects gut motility or secretion, VIP's natural role in those systems aligns with restoring balance rather than suppression alone.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- VIP → immune / autonomic\n\n## What the evidence actually shows\n\nHuman data: Observational only. One cross-sectional and prospective study of 115 adults with IBD measured VIP concentrations and found variable plasma levels that differed by disease severity (source s1). Another examined VIP nerves in Crohn's tissue and noted consistent increases and abnormal appearance in rectal samples (source s2). These show associations, not treatment effects.\n\nPreclinical data: Multiple mouse and rat studies. In TNBS-induced colitis (model sharing features with Crohn's), VIP treatment reduced clinical signs including weight loss, diarrhea, and histologic inflammation (source s3). VIP nanomedicine in DSS and TNBS mouse colitis lowered pro-inflammatory cytokines, improved histology, and supported tight junction proteins (source s4). VIP-deficient mice showed greater susceptibility to chemically induced colitis in some experiments, with exogenous VIP rescuing barrier features (source s5). Results are mixed across studies; some report exacerbation depending on model and microbiota (source s5).\n\nAnecdotal data: Limited. One Reddit thread states VIP is among the better researched compounds for Crohn's via upstream immune effects on gut lining (source s6). Other posts discuss VIP in unrelated contexts such as CIRS or Raynaud's with no IBD-specific outcomes reported.\n\n## What scientists say\n\nResearchers note VIP's immunomodulatory properties in colitis models and suggest it as a candidate for further testing in Crohn's, while highlighting inconsistent findings in knockout models and human expression data (sources s3, s5). Emphasis remains on preclinical promise rather than clinical translation.\n\n## What people say on Reddit\n\nDiscussions are sparse. Users mention VIP's anti-inflammatory profile and one notes specific research interest in Crohn's. No detailed personal outcome reports tied to IBD treatment appear in top results.\n\n## What people say on X\n\nNo relevant patient experiences or outcome reports surfaced in searches for VIP in IBD contexts.\n\n## What we do not know\n\nNo published human intervention trials test VIP administration for IBD symptom control or mucosal healing. Optimal delivery, duration, and patient selection remain untested in controlled settings. Long-term effects on human gut microbiota or barrier repair are unknown.\n\n## Safety and limits\n\nVIP is a naturally occurring peptide with documented effects in animal colitis models, but human safety data for therapeutic use in IBD do not exist in the reviewed sources. Observational human studies report no direct safety signals from measurement alone. All therapeutic claims rest on preclinical work.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/vip-ibd/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"VIP treatment reduced clinical and histologic severity in TNBS-induced colitis in mice.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Direct evidence of repair pathway effects in a Crohn's-like model.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:29:34.913Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"VIP nanomedicine lowered inflammation markers and improved barrier proteins in DSS and TNBS mouse colitis.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s4"],"source_status":"sourced","why_material":"Shows tissue-level repair signals beyond symptom masking.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:29:34.913Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"VIP plasma levels vary with IBD severity in a study of 115 patients.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Observational association only; no treatment data.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:29:34.913Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"VIP nerve changes observed in Crohn's rectal tissue samples.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Tissue-level observation in patients.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:29:34.913Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"VIP-deficient mice exhibit increased susceptibility to chemically induced colitis in some models.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s5"],"source_status":"sourced","why_material":"Supports role in barrier maintenance.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:29:34.913Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c6","text":"Reddit users note VIP research relevance to Crohn's via immune effects on gut lining.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s6"],"source_status":"sourced","why_material":"Community discussion, not outcome data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:29:34.913Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/2791804/","title":"Vasoactive intestinal peptide as a laboratory supplement to clinical testing in inflammatory bowel disease","quote":"One hundred-fifteen adult IBD patients were studied cross-sectionally and prospectively, 48 with ulcerative colitis (UC) and 67 with Crohn's disease (CD).","summary":"Observational measurement of VIP in IBD patients.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:29:32.935Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"fee95fb26e17ba61c05e452055063c3908e4ebd22d57d53cd82a56ef6e993b4e"},{"id":"s2","type":"pubmed","url":"https://gut.bmj.com/content/25/1/57","title":"Vasoactive intestinal peptide concentrations and immunocytochemistry in the colon of patients with Crohn's disease","quote":"Immunocytochemistry revealed a consistent increase in, and abnormal appearance of, VIP nerves in patients with Crohn's disease not only those with rectal...","summary":"Tissue findings in Crohn's patients.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:29:32.935Z","link_status":"http_403","quote_status":"unverified","prev":"fee95fb26e17ba61c05e452055063c3908e4ebd22d57d53cd82a56ef6e993b4e","hash":"d52d9ae4269ca5e80ee1e794e78b6d34d032d7b686efb06d6b9ae55e149de473"},{"id":"s3","type":"pubmed","url":"https://www.gastrojournal.org/article/S0016-5085(03)00055-6/fulltext","title":"Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease","quote":"Treatment with VIP reduced the clinical and histopathologic severity of TNBS-induced colitis, abrogating body weight loss, diarrhea, and macroscopic and microscopic intestinal inflammation.","summary":"Mouse TNBS colitis study showing reduced severity.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:29:32.935Z","link_status":"http_403","quote_status":"unverified","prev":"d52d9ae4269ca5e80ee1e794e78b6d34d032d7b686efb06d6b9ae55e149de473","hash":"126f99982f20657e48b5770f8c0e525f89652a833a8c0ecdf30fb69b7d4cdfb4"},{"id":"s4","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6053281/","title":"Vasoactive Intestinal Peptide Nanomedicine for the Treatment of Inflammatory Bowel Disease","quote":"We demonstrate the therapeutic benefit of VIP-SSM over free peptide in reversing severe colitis associated with IBD.","summary":"Nanomedicine improved inflammation and barrier markers in mouse models.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:29:32.935Z","link_status":"ok","quote_status":"verified","prev":"126f99982f20657e48b5770f8c0e525f89652a833a8c0ecdf30fb69b7d4cdfb4","hash":"4b8b21ae33c77c99fc987b09fd23dc1187bad497c4a9b03692618a2bcf8edbbc"},{"id":"s5","type":"pubmed","url":"https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2019.02689/full","title":"Vasoactive Intestinal Peptide Deficiency Is Associated With Dysbiosis and Altered Short-Chain Fatty Acid Levels in the Gastrointestinal Tract","quote":"In some studies, VIP knockout mice were more susceptible to chemically-induced intestinal inflammation, and human inflammatory bowel disease (IBD) patients show a reduction in VIP positive nerves proximal to severe mucosal damage.","summary":"Reviews mixed preclinical and human expression data.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:29:32.935Z","link_status":"ok","quote_status":"verified","prev":"4b8b21ae33c77c99fc987b09fd23dc1187bad497c4a9b03692618a2bcf8edbbc","hash":"ca265033e771dbdca1d8650d256ae91c52e1b1619fb4bb52da0404dc97aa1952"},{"id":"s6","type":"reddit","url":"https://www.reddit.com/r/Biohack_Blueprint/comments/1u31ihv/the_peptide_nobody_talks_about_but_everyone/","title":"The peptide nobody talks about but everyone should: VIP","quote":"VIP is actually one of the better researched compounds for Crohn's specifically. it works upstream on the immune response in the gut lining ...","summary":"Community comment on research relevance.","claim_ids":["c6"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:29:32.935Z","link_status":"ok","quote_status":"unverified","prev":"ca265033e771dbdca1d8650d256ae91c52e1b1619fb4bb52da0404dc97aa1952","hash":"d7f83bf06126e68fe70ae305e514ea16679779771ba4acf1b2066ac59b3a3eee"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T22:29:35.771Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"VIP for IBD: Evidence Graded Review of Vasoactive Intestinal Peptide in Crohn's Disease and Colitis","register":"source_ledger","body":"## What's breaking down if you have IBD (Crohn's / colitis)\n\nIf your intestinal lining loses barrier integrity, immune cells over-respond and inflammation persists. Epithelial cells fail to repair quickly enough. Nerve signaling in the gut wall shifts. These layers compound: barrier leak allows more triggers, immune imbalance sustains damage, and autonomic control of motility and secretion falters. Regeneration falls behind degeneration, so the condition continues.\n\n## Why VIP might help you\n\n1. You are reading about IBD (Crohn's / colitis) — what breaks down matters before any compound name.\n2. Therefore for you: If the immune / autonomic layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\n\nIf immune over-activation drives your mucosal damage, VIP pathways connect to reduced pro-inflammatory signals and better epithelial recovery in studied models. If autonomic imbalance affects gut motility or secretion, VIP's natural role in those systems aligns with restoring balance rather than suppression alone.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- VIP → immune / autonomic\n\n## What the evidence actually shows\n\nHuman data: Observational only. One cross-sectional and prospective study of 115 adults with IBD measured VIP concentrations and found variable plasma levels that differed by disease severity (source s1). Another examined VIP nerves in Crohn's tissue and noted consistent increases and abnormal appearance in rectal samples (source s2). These show associations, not treatment effects.\n\nPreclinical data: Multiple mouse and rat studies. In TNBS-induced colitis (model sharing features with Crohn's), VIP treatment reduced clinical signs including weight loss, diarrhea, and histologic inflammation (source s3). VIP nanomedicine in DSS and TNBS mouse colitis lowered pro-inflammatory cytokines, improved histology, and supported tight junction proteins (source s4). VIP-deficient mice showed greater susceptibility to chemically induced colitis in some experiments, with exogenous VIP rescuing barrier features (source s5). Results are mixed across studies; some report exacerbation depending on model and microbiota (source s5).\n\nAnecdotal data: Limited. One Reddit thread states VIP is among the better researched compounds for Crohn's via upstream immune effects on gut lining (source s6). Other posts discuss VIP in unrelated contexts such as CIRS or Raynaud's with no IBD-specific outcomes reported.\n\n## What scientists say\n\nResearchers note VIP's immunomodulatory properties in colitis models and suggest it as a candidate for further testing in Crohn's, while highlighting inconsistent findings in knockout models and human expression data (sources s3, s5). Emphasis remains on preclinical promise rather than clinical translation.\n\n## What people say on Reddit\n\nDiscussions are sparse. Users mention VIP's anti-inflammatory profile and one notes specific research interest in Crohn's. No detailed personal outcome reports tied to IBD treatment appear in top results.\n\n## What people say on X\n\nNo relevant patient experiences or outcome reports surfaced in searches for VIP in IBD contexts.\n\n## What we do not know\n\nNo published human intervention trials test VIP administration for IBD symptom control or mucosal healing. Optimal delivery, duration, and patient selection remain untested in controlled settings. Long-term effects on human gut microbiota or barrier repair are unknown.\n\n## Safety and limits\n\nVIP is a naturally occurring peptide with documented effects in animal colitis models, but human safety data for therapeutic use in IBD do not exist in the reviewed sources. Observational human studies report no direct safety signals from measurement alone. All therapeutic claims rest on preclinical work.","claims":[{"id":"c1","text":"VIP treatment reduced clinical and histologic severity in TNBS-induced colitis in mice.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Direct evidence of repair pathway effects in a Crohn's-like model.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:29:34.913Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"VIP nanomedicine lowered inflammation markers and improved barrier proteins in DSS and TNBS mouse colitis.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s4"],"source_status":"sourced","why_material":"Shows tissue-level repair signals beyond symptom masking.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:29:34.913Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"VIP plasma levels vary with IBD severity in a study of 115 patients.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Observational association only; no treatment data.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:29:34.913Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"VIP nerve changes observed in Crohn's rectal tissue samples.","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Tissue-level observation in patients.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:29:34.913Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"VIP-deficient mice exhibit increased susceptibility to chemically induced colitis in some models.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s5"],"source_status":"sourced","why_material":"Supports role in barrier maintenance.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:29:34.913Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c6","text":"Reddit users note VIP research relevance to Crohn's via immune effects on gut lining.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s6"],"source_status":"sourced","why_material":"Community discussion, not outcome data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:29:34.913Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/2791804/","title":"Vasoactive intestinal peptide as a laboratory supplement to clinical testing in inflammatory bowel disease","quote":"One hundred-fifteen adult IBD patients were studied cross-sectionally and prospectively, 48 with ulcerative colitis (UC) and 67 with Crohn's disease (CD).","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"pubmed","url":"https://gut.bmj.com/content/25/1/57","title":"Vasoactive intestinal peptide concentrations and immunocytochemistry in the colon of patients with Crohn's disease","quote":"Immunocytochemistry revealed a consistent increase in, and abnormal appearance of, VIP nerves in patients with Crohn's disease not only those with rectal...","link_status":"http_403","quote_status":"unverified"},{"id":"s3","type":"pubmed","url":"https://www.gastrojournal.org/article/S0016-5085(03)00055-6/fulltext","title":"Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease","quote":"Treatment with VIP reduced the clinical and histopathologic severity of TNBS-induced colitis, abrogating body weight loss, diarrhea, and macroscopic and microscopic intestinal inflammation.","link_status":"http_403","quote_status":"unverified"},{"id":"s4","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6053281/","title":"Vasoactive Intestinal Peptide Nanomedicine for the Treatment of Inflammatory Bowel Disease","quote":"We demonstrate the therapeutic benefit of VIP-SSM over free peptide in reversing severe colitis associated with IBD.","link_status":"ok","quote_status":"verified"},{"id":"s5","type":"pubmed","url":"https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2019.02689/full","title":"Vasoactive Intestinal Peptide Deficiency Is Associated With Dysbiosis and Altered Short-Chain Fatty Acid Levels in the Gastrointestinal Tract","quote":"In some studies, VIP knockout mice were more susceptible to chemically-induced intestinal inflammation, and human inflammatory bowel disease (IBD) patients show a reduction in VIP positive nerves proximal to severe mucosal damage.","link_status":"ok","quote_status":"verified"},{"id":"s6","type":"reddit","url":"https://www.reddit.com/r/Biohack_Blueprint/comments/1u31ihv/the_peptide_nobody_talks_about_but_everyone/","title":"The peptide nobody talks about but everyone should: VIP","quote":"VIP is actually one of the better researched compounds for Crohn's specifically. it works upstream on the immune response in the gut lining ...","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":14853,"tokens_out":2907,"cost":0.02583375,"prev_hash":"genesis","hash":"9e77f76cd4856e628f36d3959103976cd6901a0b2ca51a65441ee0e0e0af165c"}],"provenance":[{"ts":"2026-06-29T22:29:35.771Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Vip for Ibd\nSlug: vip-ibd\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_cross\",\"condition\":\"IBD (Crohn's / colitis)\",\"condition_key\":\"ibd-crohns-colitis\",\"primary_peptide\":\"vip\",\"peptides_in_scope\":[{\"id\":\"vip\",\"name\":\"VIP\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down if you have IBD (Crohn's / colitis)\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"vip\",\"name\":\"VIP\",\"section_title\":\"Why VIP might help you\",\"layer\":\"immune / autonomic\",\"steps\":[\"You are reading about **IBD (Crohn's / colitis)** — what breaks down matters before any compound name.\",\"**Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. You are reading about **IBD (Crohn's / colitis)** — what breaks down matters before any compound name.\\n2. **Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **VIP** → immune / autonomic\",\"section_headings\":[\"What's breaking down if you have IBD (Crohn's / colitis)\",\"Why VIP might help you\",\"How these fit together\",\"What the evidence actually show","response":"{\n  \"slug\": \"vip-ibd\",\n  \"title\": \"VIP for IBD: Evidence Graded Review of Vasoactive Intestinal Peptide in Crohn's Disease and Colitis\",\n  \"body\": \"## What's breaking down if you have IBD (Crohn's / colitis)\\n\\nIf your intestinal lining loses barrier integrity, immune cells over-respond and inflammation persists. Epithelial cells fail to repair quickly enough. Nerve signaling in the gut wall shifts. These layers compound: barrier leak allows more triggers, immune imbalance sustains damage, and autonomic control of motility and secretion falters. Regeneration falls behind degeneration, so the condition continues.\\n\\n## Why VIP might help you\\n\\n1. You are reading about IBD (Crohn's / colitis) — what breaks down matters before any compound name.\\n2. Therefore for you: If the immune / autonomic layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\\n\\nIf immune over-activation drives your mucosal damage, VIP pathways connect to reduced pro-inflammatory signals and better epithelial recovery in studied models. If autonomic imbalance affects gut motility or secretion, VIP's natural role in those systems aligns with restoring balance rather than suppression alone.\\n\\n## How these fit together\\n\\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- VIP → immune / autonomic\\n\\n## What the evidence actually shows\\n\\nHuman data: Observational only. One cross-sectional and prospective study of 115 adults with IBD measured VIP concentrations and found variable plasma levels that differed by disease severity (source s1). Another examined VIP nerves in Crohn's tissue and noted consistent increases and abnormal appearance in rectal samples (source s2). These show associations, not treatment effects.\\n\\nPreclinical data: Multiple mouse and rat studies. In TNBS-induced colitis (model sharing features with Crohn's), VIP treatment reduc","tokens_in":14853,"tokens_out":2907,"cost":0,"prev":"genesis","hash":"a94782d019f0b75f086062abb34cf43f39739266220e124c6161e8416bae1a8e"},{"ts":"2026-07-17T02:43:24.692Z","model":"owner","action":"voxel_divide","prompt":"","input":"vip-ibd","response":"22 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"a94782d019f0b75f086062abb34cf43f39739266220e124c6161e8416bae1a8e","hash":"f166b51d2487059804034ffaec44d3ff5d841148eed249f8cfe00dd198300320"}],"energy":{"passes":2,"tokens_in":14853,"tokens_out":2907,"tokens_total":17760,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"f166b51d2487059804034ffaec44d3ff5d841148eed249f8cfe00dd198300320"},"posted_at":"2026-06-29T21:33:50.665Z","created_at":"2026-06-29T21:33:50.665Z","updated_at":"2026-07-17T02:43:24.692Z","machine":{"shape":"article.machine/v1","slug":"vip-ibd","kind":"article","read":{"human":"https://miscsubjects.com/a/vip-ibd","json":"https://miscsubjects.com/api/articles/vip-ibd","bundle":"https://miscsubjects.com/api/articles/vip-ibd/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":6,"sources":6,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/vip-ibd/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=vip-ibd","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"vip-ibd\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"vip-ibd\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/vip-ibd/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"vip-ibd\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/vip-ibd | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/vip-ibd","json":"/api/articles/vip-ibd","markdown":"/api/articles/vip-ibd/bundle?format=markdown","skill":"/api/articles/vip-ibd/skill","topology":"/api/articles/vip-ibd/topology","versions":"/api/articles/vip-ibd/revisions","invocations":"/api/articles/vip-ibd/invocations"},"editorial_review":null,"editorial_audit":{"slug":"vip-ibd","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"15b4fea8778d13c60a77d0ea1bd5a2f73797e66a1cdbaff3b0a6889bfe9df25e"}}}